New York State Common Retirement Fund Sells 21,712 Shares of IQVIA Holdings Inc. (NYSE:IQV)

New York State Common Retirement Fund lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 107,928 shares of the medical research company’s stock after selling 21,712 shares during the quarter. New York State Common Retirement Fund owned approximately 0.06% of IQVIA worth $25,576,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. 1832 Asset Management L.P. increased its holdings in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after purchasing an additional 376,595 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of IQVIA during the second quarter worth about $70,610,000. Impax Asset Management Group plc increased its stake in shares of IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after buying an additional 264,555 shares during the period. Canada Pension Plan Investment Board raised its holdings in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its position in IQVIA by 285.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after buying an additional 198,808 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 1.6 %

Shares of NYSE:IQV opened at $209.16 on Monday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.85 and a current ratio of 0.81. IQVIA Holdings Inc. has a 52-week low of $181.03 and a 52-week high of $261.73. The business’s 50 day simple moving average is $234.31 and its two-hundred day simple moving average is $229.76. The firm has a market cap of $38.13 billion, a P/E ratio of 27.45, a PEG ratio of 2.01 and a beta of 1.51.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on IQV shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Friday. Morgan Stanley lifted their target price on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Evercore ISI lowered their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $263.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.